Metronome therapy: a new rhythm -new opportunities
- Autores: Chubenko V.A1
-
Afiliações:
- Clinical Scientific and Practical Center of Specialized Types for Medical Care (Oncology)
- Edição: Volume 27, Nº 7 (2020)
- Páginas: 81-84
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312730
- DOI: https://doi.org/10.18565/pharmateca.2020.7.81-84
- ID: 312730
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Modern methods of drug treatment of oncological diseases lead to an increase in life expectancy. Unfortunately, such successes, for the most part, are characteristic of a certain group of patients, taking into account specific predictive factors. In order to overcome such resistance of tumor cells, new treatment strategies are being developed. These include metronome therapy of malignant tumors. The concept of using metronome therapy is to inhibit the growth of malignant cells, which theoretically reduces the likelihood of achieving a “lethal" tumor volume and, thus, can affect survival rates.
Palavras-chave
Texto integral
Sobre autores
V. Chubenko
Clinical Scientific and Practical Center of Specialized Types for Medical Care (Oncology)
Email: vchubenko@me.com
Head of the Department of Drug Treatment (Chemotherapy of Solid Tumors) 68A, Lit. A, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation
Bibliografia
- Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
- Engel, J, Schubert-Fritschle G., Emeny R., Holzel D. Breast cancer: are long-term and intermittent endocrine therapies equally effective? J Cancer Res Clin Oncol. 2020 May 29. doi: 10.1007/s00432-020-03264-0.
- Aggarwal H, Sheffield K.M., Li L., et al. Primary tumor location and survival in colorectal cancer: A retrospective cohort study. World J Gastrointest Oncol. 2020;12(4):405-23. doi: 10.4251/wjgo. v12.i4.405.
- Yarema R., Ohorchak М., Hyrya P, et al. Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods. World J Gastrointest Oncol. 2020;12(5):569-81. doi: 10.4251/wjgo. v12.i5.569.
- Xu E, David E.A., Ding L., et al. Sequence of biologic therapies and surgery affects survival in non-small cell lung cancer. J Surg Oncol. 2020. May 20. doi: 10.1002/jso.25937.
- Cristescu R., Mogg R., Ayers M., et al. Pantumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. Doi: 10.1126/ science.aar3593.
- Murciano-Goroff Y.R., Warner A.B., Wolchok J.D. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020. doi: 10.1038/s41422-020-0337-2.
- Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045-47. Doi: 10.1172/ JCI9872.
- Abdollahi A., Hlatky L., Huber P.E. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 2005;8(1-2):59-74. Doi: 10.1016/j. drup.2005.03.001.
- Bocci G., Kerbel R.S. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13(11):659-73. doi: 10.1038/nrclinonc.2016.64.
- Andre N., et al. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014. doi: 10.1038/nrclinonc.2014.89.
- Schwartz E.L. Antivascular actions of microtubulebinding drugs. Clin Cancer Res 2009;15(8):2594-601. doi: 10.1158/1078-0432.CCR-08-2710.
- Shaked Y, Pham E., Hariharan S. Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. Cancer Res. 2016;76(20):5983-993. doi: 10.1158/0008-5472.CAN-16-0136.
- Briasoulis E., Aravantinos G., Kouvatseas G. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13(1):263. doi: 10.1186/1471-2407-13-263.
- Cazzaniga M.E., Munzone E., Bocci G. PanEuropean Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Adv Ther. 2019;36(2):381-406. doi: 10.1007/s12325- 018-0844-4
- De luliis F., Salerno G., Taglieri L., et al. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015;101(1):30-5. doi: 10.5301/tj.5000207.
- Cazzaniga M.E., Cortesi L., Ferzi A. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3):501-509. doi: 10.1007/s10549-016-4009-3.
- Montagna E., Vingiani A., Maisonneuve P. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 2017;34:83-8. doi: 10.1016/j.breast. 2017.05.009.
- Langkjer S.T., Kenholm J., Jensen J.D. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer. Future Oncol. 2019;15(22):2561-569. doi: 10.2217/fon-2019-0124.
Arquivos suplementares
